Valuation: Cocrystal Pharma, Inc.

Market Cap 20.42M 17.66M 16.49M 15.13M 28.46M 1.94B 28.91M 193M 75.95M 974M 76.67M 74.99M 3.22B P/E 2026 *
-1.55x
P/E 2027 * -1.66x
Enterprise Value 20.42M 17.66M 16.49M 15.13M 28.46M 1.94B 28.91M 193M 75.95M 974M 76.67M 74.99M 3.22B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
77.62%
Yield 2026 *
-
Yield 2027 * -
1 day+2.91%
1 week+29.27%
Current month+29.27%
1 month+4.95%
3 months-26.39%
6 months+11.44%
Current year+8.27%
1 week 0.93
Extreme 0.9258
1.09
1 month 0.76
Extreme 0.76
1.09
Current year 0.76
Extreme 0.76
2.03
1 year 0.76
Extreme 0.76
2.67
3 years 0.76
Extreme 0.76
3.26
5 years 0.76
Extreme 0.76
14.76
10 years 0.76
Extreme 0.76
194.4
Manager TitleAgeSince
Chief Executive Officer 64 2026-06-02
Chief Executive Officer 59 2021-05-26
Chief Executive Officer 66 2021-05-26
Director TitleAgeSince
Director/Board Member 89 2014-01-01
Chairman 79 2021-05-26
Director/Board Member 65 2014-01-01
Date Insider Type Main position Quantity % Market Cap.
8/5/26 Buy

Director

10,000 0.0725%
8/3/26 Buy

Director

75,000 0.5440%
2/24/26 Buy

Director

20,000 0.1451%
Change 5-day change 1-year change 3-year change Capi.($)
+2.91%+29.27%-34.57%-66.24% 20.42M
+8.49%+20.55%+70.77%+103.07% 68.12B
+1.25%+2.44%+34.27%+68.92% 55.18B
-1.09%+32.96%+19.67%+509.20% 28.63B
+10.83%+18.38%+56.20%+4.58% 23.99B
+2.72%+3.41%-16.11%-12.04% 23.53B
+6.50%+7.56%+44.65%-22.01% 18.45B
+6.20%+11.51%+33.87%+666.34% 16.44B
-3.88%+16.98%+199.30%+350.94% 15.83B
+3.58%+1.96%+43.35%+162.22% 13.4B
Average +3.75%+13.44%+45.14%+176.50% 26.36B
Weighted average by Cap. +4.36%+13.10%+50.68%+165.05%

Financials

2026 *2027 *
Net sales - -
Net income -10.5M -9.08M -8.48M -7.78M -14.63M -999M -14.87M -99.51M -39.06M -501M -39.43M -38.57M -1.66B -11.5M -9.95M -9.29M -8.52M -16.03M -1.09B -16.28M -109M -42.78M -549M -43.18M -42.24M -1.81B
Net Debt - -
Logo Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. It has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. It also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.
Employees
10
Date Price Change Volume
26-08-07 US$1.060 +2.91% 54,207
26-08-06 US$1.030 +0.98% 30,935
26-08-05 US$1.020 +4.06% 69,044
26-08-04 US$0.9802 +4.28% 116,095
26-08-03 US$0.9400 +14.63% 417,522
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.060USD
Average target price
9.000USD
Spread / Average Target
+749.06%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. COCP Stock